Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Temelimab as a Disease Modifying Therapy in Patients With Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID 19 or Postacute Sequelae of COVID-19 (PASC) Syndrome

NCT05497089 is registered in ClinicalTrials.gov with GeNeuro SA as lead sponsor.

NCT NCT05497089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05497089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Temelimab as a Disease Modifying Therapy in Patients With Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID 19 or Postacute Sequelae of COVID-19 (PASC) Syndrome
Lead sponsor
GeNeuro SA
Phase
Phase 2
Overall status
Completed
Start date
August 29, 2022
Completion date
May 10, 2024
Enrollment
203 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

post-covid-19 syndrome